BIO/PHARMA WEEKLY NEWS (10/21/19 – 10/25/19)

Let’s narrow down to five pieces of news this week. One for each day. Biogen Resurrects Aducanumab, Arguing Expanded Data Set Supports FDA Filing in Alzheimer’s (FierceBiotech) Biogen hit headline in March when they halted both Phase 3 trials EMERGE and ENGAGE; This week, their news on reviving the once-abandoned drug aducanumab was on front…

BIO/PHARMA WEEKLY NEWS (10/12/2019 – 10/18/2019)

What headlines caught your attention this week? ❖❖❖ Innovations ❖❖❖ Pfizer Posts Detailed Phase 3 Data on Its Dupixent Rival (Fierce Biotech) Pfizer’s JAK1 inhibitor—acrocitinib is a potential challenge to Sanofi and Regeneron’s atopic dermatitis drug Dupixent. In their previous Phase 3 trial, 43.8% of subjects treated with acrocitinib showed clear or almost clear skin, compared with…

We Need More “Yes” and “I Can” from Women

There were dark days that woman’s contributions were not appropriately acknowledged. Drs. James Watson and Francis Crick published their landmark discovery-the structure of DNA, but Rosalind Franklin was not mentioned a single time. Fortunately, ignoring women’s contribution is past tense. However, women keep disappearing as they move up the career ladder in the corporate environment,…

Pitch Perfect, Scientifically!

Imagine your science worked perfectly fine, now what? You realize the tough work has just begun because you need $$$$! You were given five minutes to encapsulate your scientific innovation, market analysis, product competitive advantage, and the credibility of your team. And another five minutes to answer questions (sometimes unforeseen) from the investors. How would…

360-Degree View of the Scientific News

We are warned not just listen to one side of the story. The same advice applies when you digest the biotech news. This August, Adamas made headline because its drug Gocovri gained the FDA’s first approval to treat levodopa-induced dyskinesia, an involuntary movement disorder occurred in 90% of the levodopa-treated Parkinson patients. Do you think…

Lost Farmers

当我还是小孩子的时候,有一天一位老师在课堂上讲述到美国人口仅2%是农民却足以养活一个国家。她激情澎湃得说到:这就是农业工业化的力量!当时懵懂的我们眼里全是美国农民指尖一按,就有各种机械纷涌而至帮他们丰衣足食的美好景象。对比当年我们中国人口80%都是农民,却仍不能夸口农产品丰盛,实为惭愧。 而今,我在Santa Monica海滩边一个独立影院Laemmle Theater看着独立影片《Look & See – A Portrait of Wendell Berry》。纪录片里,真正的美国农民把当年老师给我们中国孩子们描绘的美国农业的美景撕得面目全非。没错,工业机械化确实如同几百年前美国土著印第安人得了欧洲的马一般如有神助。欧洲马在美洲大陆上如同野草一般繁殖,然而重型机械无法有性繁殖,庞大的支出和维护并非一般农民可以承受。为了避免入不敷出,美国农民只能硬着头皮扩增农场的大小,然后最终却把自己弄得疲惫不堪。他们向往的与大地亲密接触的小型农场只是一个遥不可及的梦。虽然我不同意纪录片中对工业化的所有批评,但我非常欣赏Wendell Berry先生忧农民之忧,敢于警世现代工业的弊端。 纪录片里引用了一张美国农业部调查报告图,显示美国农场的数量急剧下降,然而农场大小却在盲目扩张。我没有找到同一张图,且用下图代替。 [http://nwdistrict.ifas.ufl.edu/phag/2016/03/04/population-growing-but-us-farm-acreage-declining/]   Lining playing the theme song of Castle in the Sky. 配乐为我演奏的《天空之城》的主题曲。虽与农业无关,但也是关于保护可贵资源以免落入贪婪之手。

“Print Life on Mars” Prequel

We all agree that a smarter way of manufacturing is urgently needed to keep up with the rapid growth in the biotech industry. This Nature Biotechnology article took us for a ride to not-too-far-in-the-future, on-demand, small-scale, automated manufacturing of biologics. The scientists at the Synthetic Genomics named this invention digital-to-biological converter (DBC). Interestingly when I…

Speaking Is An Act of Service

My blog is my X-large size notepad on the Cloud. This article is modified from my notes to Daniel Midson-Short’s keynote speech – the Emerging Speaker – at the Toastmasters Founders District LACE training at Caltech. I simply want to share my learning, for writing is also an act of service. Daniel mentioned that rookies make three common…

Life is An Amazing Road Trip

Yes, I am a scientist. Ironically, the biggest awards I got in my life have nothing to do with science. My three province-level awards in my teenage years are from speech competitions, a piano competition, and a writing contest. My hometown province has a population size like the one in California. Later on, I didn’t…